- Strong interest in ProSense from healthcare
providers in Canada strengthens
market potential
- ProSense now approved throughout North America
CAESAREA, Israel, July 24,
2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer of the ProSense®
System, a minimally-invasive cryoablation technology that destroys
tumors by freezing as an alternative to surgical tumor removal,
today announced that Health Canada, the Canadian government's
regulatory agency, has approved IceCure's ProSense System,
disposable cryoprobes, and introducers as cryosurgical tools for
indications including:
- Tumors – ablation of benign and malignant tumors of the lung,
liver, kidneys, and musculoskeletal system, and benign tumors
of the breast;
- General surgery;
- Palliative intervention; and
- Other surgeries.
"As we continue to gain traction in the United States, this approval in
Canada will create synergies for
us in the broader North American market. We have been directly
engaging with healthcare providers through education, hands-on
training seminars, marketing, and sales in the U.S. and we will
expand these activities into Canada. We have already been contacted by
multiple Canadian healthcare providers with requests to purchase
and implement ProSense," stated IceCure Chief Executive Officer,
Eyal Shamir.
Canada's healthcare system is
ranked as one of the top in the world, with total health spending
estimated at $331 billion in
2022.
IceCure's cryoablation system currently has regulatory approval
for various indications in 15 countries, including in the U.S.,
Europe, and China.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses how
Health Canada's regulatory approval will create synergies for the
Company in the North American market and how the Company will
expand education, hands-on training seminars, marketing, and sales
into Canada. Because such
statements deal with future events and are based on IceCure's
current expectations, they are subject to various risks and
uncertainties and actual results, performance, or achievements of
IceCure could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company's Annual Report on Form 20-F for the
year ended December 31, 2022 filed
with the SEC on March 29, 2023, and
other documents filed with or furnished to the SEC which are
available on the SEC's website, www.sec.gov. The Company undertakes
no obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Michael
Polyviou
Email: mpolyviou@evcgroup.com
732-232-6914
Todd Kehrli
Email: tkehrli@evcgroup.com
310-625-4462
View original
content:https://www.prnewswire.com/news-releases/health-canada-approves-icecure-medicals-minimally-invasive-prosense-cryoablation-system-301883778.html
SOURCE IceCure Medical